Illuminating the
right decisions
for your patients

Illuminating the
right decisions
for your patients

Our technology illuminates medical diagnosis with single draw of blood. Driving this advancement is our patented technology and AI-powered clinical analytics. Compared to conventional approaches, we can diagnose cancer in a faster, cheaper and simpler way. Our genomic tests enable physicians to make more informed clinical decisions - with the singular goal of improving patients' lives.

Genomic Medicine.
A new horizon of hope.

Our portfolio of genomic tests covers cancer
screening and tumor treatment, enabling better patient care.

Cancer Tests for Better Treatment
and Management of Patients

See our full range of diagnostic services.

Early Detection

Most cancers are currently detected in the late stages with poor treatment outcome and high treatment costs. The early detection of cancer will improve cancer survival rates and chances of cure. Our blood test can detect nasopharyngeal or nose cancer earlier before symptoms show. In addition, we are currently developing a blood test for the early detection of multiple cancers.

NPC GOLDTM

Early cancer detection test for nasopharyngeal cancer

Learn more

Genetic Testing

Cancer is caused by changes called mutations in our genes. When one gene mutation is passed from one generation to another, hereditary cancers can occur. Having these mutations does not mean you will get cancer. However, they increase your risk of cancer. Genetic testing can help determine a person’s risk for developing cancer in your lifetime.

LumiRISKTM

A multi-cancer blood test that detects gene mutations associated with cancer risk

Learn more

LumiFOCUSTM

A blood test that detects gene mutations associated with a specific cancer risk

Learn more

Treatment Selection and Monitoring

In recent years, the treatment of cancer has shifted from a one-size-fits-all approach using chemotherapy, which kills all cells including healthy cells to targeted therapy, which kills only cancer cells and have less side effects. Based on clinical studies, certain genetic mutations have been shown to respond better to specific targeted drugs. Our blood tests identify the genetic mutations in each tumor to find the right drug for the right patient. Our tests can also help to monitor treatment response and signs of cancer recurrence.

LiquidHALLMARK®

Our flagship blood test that detects multiple cancer-causing gene mutations and viruses

Learn more

LiquidSCREENTM & LiquidTRACKTM

Blood tests that detect and track specific cancer-causing gene mutations

Learn more

LumiBRCATM & LumiTHERATM

Companion diagnostic tests that detect specific gene mutations in breast or ovarian cancers

Learn more

Breast Tumor Treatment

Fibroadenoma is the most common benign breast tumor in the world. Phyllodes tumor is a less common tumor that can be malignant; it can also recur even after being removed. It can be hard to differentiate between these two types of tumors because they share overlapping clinical and histological features. Our test distinguishes a fibroadenoma from a phyllodes tumor to help doctors decide how to treat a breast lump that has been detected.

FibroPhylloTM Tissue

A molecular tissue test to determine whether a breast lump is a fibroadenoma or phyllodes tumor

Learn more

Workflow for Ordering a Lucence Test

Physician submits patient blood sample to Lucence

Lucence performs laboratory testing and generate test report with clinical interpretation

Lucence delivers test report to physician within the promised turnaround time

Click here to view a Sample Lucence Test Report

To order our tests, please call or email us. Our customer care team will assist you on the ordering process.

FAQ

How can genomic testing help my patients?

Genomic testing is used to identify genetic mutations in the tumor to improve treatment selections for your patients. The presence or absence of certain mutations can predict who may benefit from certain drugs and who is not likely to respond. This helps to match your patients to the right treatment. We also have a test for early detection of nasopharyngeal cancer to enable earlier treatment. Our tests can also check whether a person is predisposed to cancer by detecting genes commonly associated with increased risk of cancer.

What is the accuracy rate of your tests?

All our diagnostic tests are clinically validated for accuracy and performed in our ISO 15189 accredited molecular diagnostics laboratory. Lucence also participates in external quality assessments to ensure that our tests meet industry benchmarks. We have achieved top-tier performance for our tests by international external quality assessment organizations such as the Quality Control for Molecular Diagnostics, and the European Molecular Genetics Quality Network .

What is the test turnaround time?

This depends on the type of test ordered which can range from one day to 21 days. Please check the test pages for details.

What technology is used in your tests?

Our tests are based on proprietary technology, which detects genomic alterations in tumor with higher sensitivity and accuracy than comparable approaches.

What countries are your tests available in?

Our tests are currently available across ASEAN and Hong Kong. Please contact our customer care team for further enquiries.

Need Help?